Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, Eichberg JW.

Nature. 1990 Jun 14;345(6276):622-5.

PMID:
2190095
2.

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

[No authors listed]

Dis Markers. 1991 Jan-Feb;9(1):51. No abstract available.

PMID:
1742945
3.

HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.

Bruck C, Thiriart C, Fabry L, Francotte M, Pala P, Van Opstal O, Culp J, Rosenberg M, De Wilde M, Heidt P, Heeney J.

Vaccine. 1994 Sep;12(12):1141-8.

PMID:
7998425
5.
6.

Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.

Moore JP, McKeating JA, Jones IM, Stephens PE, Clements G, Thomson S, Weiss RA.

AIDS. 1990 Apr;4(4):307-15.

PMID:
2190605
7.
8.

Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.

Natuk RJ, Chanda PK, Lubeck MD, Davis AR, Wilhelm J, Hjorth R, Wade MS, Bhat BM, Mizutani S, Lee S, et al.

Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7777-81.

9.

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

Girard M, Meignier B, Barré-Sinoussi F, Kieny MP, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K, et al.

J Virol. 1995 Oct;69(10):6239-48.

10.

Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Pincus SH, Messer KG, Schwartz DH, Lewis GK, Graham BS, Blattner WA, Fisher G.

J Clin Invest. 1993 May;91(5):1987-96.

11.

HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques.

Abimiku AG, Franchini G, Tartaglia J, Aldrich K, Myagkikh M, Markham PD, Chong P, Klein M, Kieny MP, Paoletti E, et al.

Nat Med. 1995 Apr;1(4):321-9.

PMID:
7585061
12.

Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines.

Israel ZR, Edmonson PF, Maul DH, O'Neil SP, Mossman SP, Thiriart C, Fabry L, Van Opstal O, Bruck C, Bex F, et al.

J Virol. 1994 Mar;68(3):1843-53.

13.

Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

Berman PW, Murthy KK, Wrin T, Vennari JC, Cobb EK, Eastman DJ, Champe M, Nakamura GR, Davison D, Powell MF, Bussiere J, Francis DP, Matthews T, Gregory TJ, Obijeski JF.

J Infect Dis. 1996 Jan;173(1):52-9.

14.

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, et al.

J Infect Dis. 1993 Mar;167(3):533-7.

PMID:
8095059
15.

Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.

Berman PW, Groopman JE, Gregory T, Clapham PR, Weiss RA, Ferriani R, Riddle L, Shimasaki C, Lucas C, Lasky LA, et al.

Proc Natl Acad Sci U S A. 1988 Jul;85(14):5200-4.

16.

Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.

Shiver JW, Perry HC, Davies ME, Freed DC, Liu MA.

Ann N Y Acad Sci. 1995 Nov 27;772:198-208.

PMID:
8546393
17.

Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.

Mossman SP, Bex F, Berglund P, Arthos J, O'Neil SP, Riley D, Maul DH, Bruck C, Momin P, Burny A, Fultz PN, Mullins JI, Liljeström P, Hoover EA.

J Virol. 1996 Mar;70(3):1953-60.

18.

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.

Bolmstedt A, Sjölander S, Hansen JE, Akerblom L, Hemming A, Hu SL, Morein B, Olofsson S.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):213-20.

PMID:
8673525
20.

Human studies in the development of human immunodeficiency virus vaccines.

Dolin R.

J Infect Dis. 1995 Nov;172(5):1175-83. Review.

PMID:
7594651
Items per page

Supplemental Content

Write to the Help Desk